- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03183908
FLUAD® vs. Fluzone® High-Dose Study
Safety and Immunogenicity of Adjuvanted Versus High-Dose Inactivated Influenza Vaccines in Older Adults
Study Overview
Status
Intervention / Treatment
Detailed Description
Full Analysis Population 1: Defined as all subjects who are randomized, vaccinated, and provide at least one day of complete data on the symptom diary.
Full Analysis Population 2: Defined as all subjects who are randomized and vaccinated.
Immunogenicity Population: Defined as subjects who received vaccine, provided baseline and Visit 4 blood draws of acceptable volume and quality within the protocol-defined time frame with no protocol violations affecting immunogenicity.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30333
- Centers for Disease Control and Prevention
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02118
- Boston Medical Center
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Duke University
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Cincinnati Children's Hospital Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Persons aged ≥65 years, living in the community
- Intention of receiving IIV vaccine based on ACIP-CDC guidelines
- Willing to provide written informed consent prior to initiation of any study procedures
- Able to speak English
- Able and willing to complete baseline assessments and questionnaires, and to allow information to be collected from their electronic medical record
- Able and willing to complete post-vaccine assessments and questionnaires independently or with assistance
- Able and willing to have blood drawn for the study
- Able and willing to return in about one month for a follow-up visit including completing questionnaires and having another blood test
- Access to and ability to use a phone, independently or with assistance
- Adequate vision and motor skills to complete the diary form independently or with assistance.
- Not living in a skilled nursing facility/nursing home/long term acute care facility
Exclusion Criteria:
- IIV receipt during the current influenza season prior to study enrollment
Enrolled in this study during the 2017-18 (Year 1) influenza season
Note: Year 1 study participants will only be enrolled in Year 2 if they are participating in the sub-study on repeat vaccination
- Has immunosuppression as a result of an underlying illness or treatment, or use of anti-cancer chemotherapy or radiation therapy within the preceding 12 months.
Has an active neoplastic disease (excluding non-melanoma skin cancer or prostate cancer that is stable in the absence of therapy) or a history of any hematologic malignancy*
*Participants with a history of malignancy may be included if, after previous treatment by surgical excision, chemotherapy or radiation therapy, the participant has been observed for a period that in the investigator's estimation provides a reasonable assurance of sustained cure (not less than 12 months)
- Thrombocytopenia, bleeding disorder, or anticoagulant use contraindicating intramuscular injection
- History of febrile illness (> 100.0°F or 37.8°C) within the past 24 hours prior to IIV administration (temporary deferral)
Contraindication to IIV receipt including history of severe allergic reaction after a previous dose of any influenza vaccine; or to a vaccine component*, including egg protein; or a latex allergy
*Formaldehyde, Octylphenol ethoxylate, neomycin, kanamycin, barium, cetyltrimethlyammonium bromide (CTAB)
- Any history of Guillain-Barré syndrome
- Mild to severe dementia as determined by the Mini-Cog tool and the Rowland Universal Dementia Assessment Scale (RUDAS)
- Substance use that could interfere with study compliance
- Receipt of any inactivated licensed vaccine within 2 weeks, or live attenuated licensed vaccine within 4 weeks prior to enrollment in this study, or planning receipt of any vaccines during the 42-days post-vaccination period (including pneumococcal vaccines)
- Anyone who is already enrolled or plans to enroll in another clinical trial with an investigational product within 28 days of vaccine receipt. Co-enrollment in observational or behavioral intervention studies are allowed at any time while enrollment in a clinical trial involving an investigational product (other than vaccine) may occur after 30 days following vaccine receipt.
- Hearing loss determined by the investigators to prevent successful communication over the phone
- Any condition which, in the opinion of the investigators, may pose a health risk to the subject or interfere with the evaluation of the study objectives.
- Anyone who is a relative or subordinate of any research study personnel.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Adjuvanted influenza vaccine (FLUAD®)
In the study arm, subjects will receive a single dose of FLUAD® adjuvanted influenza vaccine during Visit 1.
|
Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine
Other Names:
|
Active Comparator: High-dose influenza vaccine (Fluzone® HD)
In the study arm, subjects will receive a single dose of Fluzone® High-Dose influenza vaccine during Visit 1.
|
Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Injection-Site Pain in Arm That Was Vaccinated, Population 1
Time Frame: Days 1 through 8 post-vaccination
|
Comparison of the proportion of subjects reporting moderate/severe injection site pain within the first week post-vaccination in both treatment groups.
|
Days 1 through 8 post-vaccination
|
Number of Participants With Adverse Events of Clinical Interest, Population 2
Time Frame: 42 days post-vaccination and compared between the two groups.
|
The frequency and descriptions of adverse events of clinical interest observed in the two treatment groups.
|
42 days post-vaccination and compared between the two groups.
|
Observed Serious Adverse Events in Both Treatment Groups, Population 2
Time Frame: 42 days post-vaccination and compared between the two groups.
|
The frequency and descriptions of serious adverse events observed in the two treatment groups. No analytical analysis was completed. |
42 days post-vaccination and compared between the two groups.
|
Number of Participants With H3N2 HAI Seroconversion
Time Frame: 29 days post-vaccination
|
H3N2 hemagglutination inhibition assay (HAI) seroconversion: The proportion of subjects achieving H3N2 seroconversion at day 29 (an HAI titer > 1:40 at day 29 if the baseline titer is < 1:10 or a four-fold rise in HAI titer if the baseline titer is > 1:10) in the respective season's vaccine
|
29 days post-vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Local Reactions in Arm That Was Vaccinated - Full Study, Population 1
Time Frame: Days 1 through 8 post-vaccination
|
Comparison of local reactions within the first week post-vaccination in both treatment groups.
|
Days 1 through 8 post-vaccination
|
Number of Participants With Local Reactions in Arm That Was Vaccinated - Ages 65 - 79, Population 1
Time Frame: Days 1 through 8 post-vaccination
|
Comparison of local reactions within the first week post-vaccination in both treatment groups by age group.
|
Days 1 through 8 post-vaccination
|
Number of Participants With Local Reactions in Arm That Was Vaccinated - Ages 80 +, Population 1
Time Frame: Days 1 through 8 post-vaccination
|
Comparison of local reactions within the first week post-vaccination in both treatment groups by age group.
|
Days 1 through 8 post-vaccination
|
Number of Participants With Systemic Reactions - Full Study Population, Population 1
Time Frame: Days 1 through 8 post-vaccination
|
Comparison of systemic reactions within the first week post-vaccination in both treatment groups.
|
Days 1 through 8 post-vaccination
|
Number of Participants With System Reactions - Ages 65 - 79, Population 1
Time Frame: Days 1 through 8 post-vaccination
|
Comparison of systemic reactions within the first week post-vaccination in both treatment groups by age group.
|
Days 1 through 8 post-vaccination
|
Number of Participants With System Reactions - Ages 80 +, Population 1
Time Frame: Days 1 through 8 post-vaccination
|
Comparison of systemic reactions within the first week post-vaccination in both treatment groups by age group.
|
Days 1 through 8 post-vaccination
|
Quality of Life - Late Life Function & Disability Instrument - Full Population
Time Frame: Pre-vaccination (Day 1), 2 days post-vaccination (Day 3)
|
Change in scores on the Late Life Function & Disability Instrument pre-vaccination to post-vaccination (Day 1 - Day 3) compared between the vaccination groups (Year 1 only). Response choices are ranked 1-5, High Scores indicate better outcomes. The Function/Activity Scale measured the amount of difficulty in completing a range of activities, or the amount of help required in doing an activity due to physical or mental heath. : None (5); A little (4) ; Some (3), Quite a lot (2), and Cannot Do (1). The Disability/Participation Scale measured participation levels in social, family, and community activities due to physical or mental health. Each question has two parts. For the first part of the question, response choices include: Very often (5), Often (4), Once in a while (3), Almost never (2), Never (1). For the second part of the question, response choices include: Not at all (5), A little (4), Somewhat (3), A lot (2), and Completely (1). |
Pre-vaccination (Day 1), 2 days post-vaccination (Day 3)
|
Quality of Life - Late Life Function & Disability Instrument - Ages 65 - 79
Time Frame: Pre-vaccination (Day 1), 2 days post-vaccination (Day 3)
|
Change in scores on the Late Life Function & Disability Instrument pre-vaccination to post-vaccination (Day 1 - Day 3) compared between the vaccination groups (Year 1 only). Response choices are ranked 1-5, High Scores indicate better outcomes. The Function/Activity Scale measured the amount of difficulty in completing a range of activities, or the amount of help required in doing an activity due to physical or mental heath. : None (5); A little (4) ; Some (3), Quite a lot (2), and Cannot Do (1). The Disability/Participation Scale measured participation levels in social, family, and community activities due to physical or mental health. Each question has two parts. For the first part of the question, response choices include: Very often (5), Often (4), Once in a while (3), Almost never (2), Never (1). For the second part of the question, response choices include: Not at all (5), A little (4), Somewhat (3), A lot (2), and Completely (1). |
Pre-vaccination (Day 1), 2 days post-vaccination (Day 3)
|
Quality of Life - Late Life Function & Disability Instrument - Ages 80 +
Time Frame: Pre-vaccination (Day 1), 2 days post-vaccination (Day 3)
|
Change in scores on the Late Life Function & Disability Instrument pre-vaccination to post-vaccination (Day 1 - Day 3) compared between the vaccination groups (Year 1 only). Response choices are ranked 1-5, High Scores indicate better outcomes. The Function/Activity Scale measured the amount of difficulty in completing a range of activities, or the amount of help required in doing an activity due to physical or mental heath. : None (5); A little (4) ; Some (3), Quite a lot (2), and Cannot Do (1). The Disability/Participation Scale measured participation levels in social, family, and community activities due to physical or mental health. Each question has two parts. For the first part of the question, response choices include: Very often (5), Often (4), Once in a while (3), Almost never (2), Never (1). For the second part of the question, response choices include: Not at all (5), A little (4), Somewhat (3), A lot (2), and Completely (1). |
Pre-vaccination (Day 1), 2 days post-vaccination (Day 3)
|
Quality of Life - EQ-5D-5L -Full Population
Time Frame: Pre-vaccination (Day 1), 2 days post-vaccination (Day 3)
|
Change in scores on the EuroQOL 5 dimensions-5 level (EQ-5D-5L) pre-vaccination and post-vaccination compared between the vaccination groups (Year 1 only). Responses on the EQ-5D-5L measure is converted to a Utility Index that ranges from -0.109 (worst health) to 1.000 (best health). |
Pre-vaccination (Day 1), 2 days post-vaccination (Day 3)
|
Quality of Life - EQ-5D-5L - Ages 65 - 79
Time Frame: Pre-vaccination (Day 1), 2 days post-vaccination (Day 3)
|
Change in scores on the EuroQOL 5 dimensions-5 level (EQ-5D-5L) pre-vaccination and post-vaccination compared between the vaccination groups and age group (Year 1 only). Responses on the EQ-5D-5L measure is converted to a Utility Index that ranges from -0.109 (worst health) to 1.000 (best health). |
Pre-vaccination (Day 1), 2 days post-vaccination (Day 3)
|
Quality of Life - EQ-5D-5L - Ages 80 +
Time Frame: Pre-vaccination (Day 1), 2 days post-vaccination (Day 3)
|
Change in scores on the EuroQOL 5 dimensions-5 level (EQ-5D-5L) pre-vaccination and post-vaccination compared between the vaccination groups and age group (Year 1 only) Responses on the EQ-5D-5L measure is converted to a Utility Index that ranges from -0.109 (worst health) to 1.000 (best health). |
Pre-vaccination (Day 1), 2 days post-vaccination (Day 3)
|
Quality of Life - EQ VAS -Full Population
Time Frame: Pre-vaccination (Day 1), 2 days post-vaccination (Day 3)
|
Change in scores on the EuroQOL visual analogue scale (EQ VAS) pre-vaccination and post-vaccination compared between the vaccination groups (Year 1 only). The EQ VAS records the respondent's self-rated health on a 20 cm vertical, visual analogue scale with endpoints labelled 'the best health you can imagine' (100) and 'the worst health you can imagine' (0). |
Pre-vaccination (Day 1), 2 days post-vaccination (Day 3)
|
Quality of Life - EQ VAS - Ages 65 - 79
Time Frame: Pre-vaccination (Day 1), 2 days post-vaccination (Day 3)
|
Change in scores on the EuroQOL visual analogue scale (EQ VAS) pre-vaccination and post-vaccination compared between the vaccination groups and age group (Year 1 only). The EQ VAS records the respondent's self-rated health on a 20 cm vertical, visual analogue scale with endpoints labelled 'the best health you can imagine' (100) and 'the worst health you can imagine' (0). |
Pre-vaccination (Day 1), 2 days post-vaccination (Day 3)
|
Quality of Life - EQ VAS - Ages 80 +
Time Frame: Pre-vaccination (Day 1), 2 days post-vaccination (Day 3)
|
Change in scores on the EuroQOL visual analogue scale (EQ VAS) pre-vaccination and post-vaccination compared between the vaccination groups and age group (Year 1 only). The EQ VAS records the respondent's self-rated health on a 20 cm vertical, visual analogue scale with endpoints labelled 'the best health you can imagine' (100) and 'the worst health you can imagine' (0). |
Pre-vaccination (Day 1), 2 days post-vaccination (Day 3)
|
Seroconversion - 65 and Older
Time Frame: Day 29 (28 days post-vaccination)
|
The proportion of subjects achieving seroconversion at day 29 (an HAI titer > 1:40 at day 29 if the baseline titer is < 1:10 or a four-fold rise in HAI titer if the baseline titer
|
Day 29 (28 days post-vaccination)
|
Seroprotection - 65 and Older
Time Frame: Day 29 (28 days post-vaccination)
|
Proportion of subjects with a seroprotective HAI titer (≥ 1:40) pre- and post-immunization at day 29 for each IIV antigen in the respective season's vaccine
|
Day 29 (28 days post-vaccination)
|
Geometric Mean HAI Titer - 65 and Older
Time Frame: Day 29 (28 days post-vaccination)
|
The geometric mean HAI titer (GMT) for each IIV antigen in the respective season's vaccine
|
Day 29 (28 days post-vaccination)
|
Seroconversion - Ages 65-79
Time Frame: Day 29 (28 days post-vaccination)
|
The proportion of subjects aged 65-79 achieving seroconversion at day 29 (an HAI titer > 1:40 at day 29 if the baseline titer is < 1:10 or a four-fold rise in HAI titer if the baseline titer
|
Day 29 (28 days post-vaccination)
|
Seroconversion - Ages 80 and Older
Time Frame: Day 29 (28 days post-vaccination)
|
The proportion of subjects ages 80 and older achieving seroconversion at day 29 (an HAI titer > 1:40 at day 29 if the baseline titer is < 1:10 or a four-fold rise in HAI titer if the baseline titer
|
Day 29 (28 days post-vaccination)
|
Seroprotection - Ages 65-79
Time Frame: Day 29 (28 days post-vaccination)
|
Proportion of subjects ages 65-79 with a seroprotective HAI titer (≥ 1:40) pre- and post-immunization at day 29 for each IIV antigen in the respective season's vaccine
|
Day 29 (28 days post-vaccination)
|
Seroprotection - Ages 80 and Older
Time Frame: Day 29 (28 days post-vaccination)
|
Proportion of subjects ages 80 and older with a seroprotective HAI titer (≥ 1:40) pre- and post-immunization at day 29 for each IIV antigen in the respective season's vaccine
|
Day 29 (28 days post-vaccination)
|
Geometric Mean HAI Titer - Ages 65-79
Time Frame: Day 29 (28 days post-vaccination)
|
The geometric mean HAI titer (GMT) for each IIV antigen in the respective season's vaccine for ages 65-79
|
Day 29 (28 days post-vaccination)
|
Geometric Mean HAI Titer - Ages 80 and Older
Time Frame: Day 29 (28 days post-vaccination)
|
The geometric mean HAI titer (GMT) for each IIV antigen in the respective season's vaccine for ages 80 and older
|
Day 29 (28 days post-vaccination)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Kenneth Schmader, MD, Duke University
- Principal Investigator: Elizabeth Barnett, MD, Boston University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00083845
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Quality of Life
-
Assiut UniversityUnknownImproving Quality of LifeEgypt
-
B. Braun Medical SAUnknownQuality of Life of Colostomized Patient
-
Children's National Research InstituteRecruitingProfessional Quality of LifeUnited States
-
Istituto Ortopedico RizzoliUniversity of BolognaRecruitingImprove Quality of LifeItaly
-
Mattu UniversityCompletedBreif Description: Patients' Quality of Life ofEthiopia
-
University of South CarolinaNational Institute on Minority Health and Health Disparities (NIMHD)RecruitingHealth Related Quality of LifeUnited States
-
PharmanexSprim Advanced Life SciencesCompletedHealth-related Quality of LifeUnited States
-
Region VästmanlandUnknownHealth Related Quality of Life
-
Ain Shams UniversityCompletedHealth Related Quality of LifeEgypt
-
Institute of Oncology LjubljanaUnknownHealth-related Quality of LifeSlovenia
Clinical Trials on FLUAD®
-
Chiltern Pesquisa Clinica LtdaCompletedDiabetes Mellitus | Chronic Pulmonary Disease | Chronic Heart Disease | H1N1 Influenza VirusBrazil
-
Canadian Immunization Research NetworkCHU de Quebec-Universite Laval; McGill University Health Centre/Research Institute... and other collaboratorsCompleted
-
ModernaTX, Inc.Active, not recruitingCytomegalovirus | SARS-CoV-2 | Seasonal Influenza | Respiratory Syncytial VirusUnited States
-
Korea University Guro HospitalNovartisCompletedPneumococcal Infections | Influenza, Human
-
GlaxoSmithKlineCompletedRespiratory Syncytial Virus InfectionsFrance, Finland, Belgium, Spain, United Kingdom
-
University Hospital, GhentGlaxoSmithKline; Novartis Vaccines; University of Surrey; Innovative Medicines... and other collaboratorsCompletedSafety Markers of Adjuvanted Influenza VaccineBelgium
-
University Health Network, TorontoCompletedTransplantation | Influenza Vaccines
-
University of SurreyMax Planck Institute for Infection BiologyCompleted
-
Yale UniversityNational Institute of Allergy and Infectious Diseases (NIAID)Recruiting
-
Korea University Guro HospitalCompletedChronic Kidney Disease | Influenza | End Stage Renal Failure